Type: Oral
Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Lineage Tracing and Novel Target Discovery
Hematology Disease Topics & Pathways:
Research, Fundamental Science
Jak2VF mice exhibited leukocytosis and thrombocytosis, and TYK2 deficiency had no effect on MPN phenotypes induced by Jak2VF. IFN-α treatment was associated with a significant reduction in leukocyte and platelet counts in Jak2V617F mice. In contrast, leukocyte and platelet counts remained unchanged after IFN-α treatment in Jak2V617F and Tyk2-/- mice. The proportions of BM progenitor cells as MEP and megakaryocyte lineage cells as MKP were markedly decreased by IFN-α treatment in Jak2V617F mice, whereas IFN-α had no effect on their proportions in Jak2V617F;Tyk2-/- mice. Next, we assessed the effects of IFN-a on cytokine-dependent colony formation. The colony numbers of CFU-GM and CFU-Meg from Jak2V617F mice decreased by about half in the presence of IFN-a. In contrast, cytokine-dependent colony formation was not affected by the presence of IFN-a in Jak2V617F;Tyk2-/- mice. GSEA revealed significant enrichment of genes regulating antiproliferation in IFN-α-treated Jak2VF GMPs, but not in IFN-α-treated GMPs from Jak2V617F;Tyk2-/- mice. Collectively, these results indicate that TYK2 plays an essential role in the antiproliferative effect of IFN-α on Jak2VF progenitors.
IFN-α was reported to induce HSCs to enter the cell cycle. The significant reduction in quiescent cells and increase in cycling LT-HSCs in Jak2VF compared to WT HSCs after IFN-α treatment was reported (Mullally et al. Blood 2013). Consistent with previous reports, the proportion of long-term HSCs in BM from Jak2VF mice was decreased by 8-weeks-IFN-α treatment, however, this IFN-α effect was not observed when TYK2 was absent. In the pool of phenotypic long-term HSCs, there are subsets of stem cells with an intrinsic megakaryocytic bias and a propensity to commit directly to the megakaryocytic lineage. In the JAK2VF mutant fraction of HSCs from recipient mice transplanted with JAK2VF and WT BM cells, IFN-α treated mice were reported to show an increase in the percentage of CD41high, megakaryocyte-skewed HSCs (Rao et al. Blood 2021). Consistent with this report, IFN-α treatment increased the proportion of CD41highHSCs and decreased that of CD41lowHSCs in BM from Jak2VF mice, and again, IFN-α-induced megakaryocytic bias of HSCs was not observed in TYK2 deficient HSCs. IFN-α had similar effect on Jak2VF-HSCs in recipient mice transplanted with Jak2VF and WT BM cells, and this IFN-α effect was not observed when TYK2 was absent. These observations indicate that TYK2 is essential for the effects of IFN-α on HSCs.
These results indicate that TYK2 is indispensable for the effects of IFN-α on improvement of MPN features.
Disclosures: Tahira: PharmaEssentia: Research Funding.
See more of: Oral and Poster Abstracts